Navigation Links
Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
Date:7/31/2008

ade pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigati
'/>"/>
SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
4. Horizon Therapeutics Announces Corporate Relocation to the Chicago Area
5. Genta Announces Second Quarter 2008 Financial Results and Conference Call
6. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
7. PURE Bioscience Announces DuraBan International as Distributor of SDC-Based Disinfectant
8. Bioheart, Inc. Announces Financial Results for Second Quarter 2008
9. Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
10. Bioheart, Inc. Announces Results of Annual Meeting
11. Geecf: Spectrum Blue Steel Announces Strategic Partnership with Al Manhal International Group of Abu Dhabi to Deploy Biosphere Facilities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Ottawa, ON (PRWEB) April 28, 2015 ... CEO and founder, has been selected by the Ottawa ... 40 Under 40. Dr. Lem was selected from over ... and community involvement. , Prior to Spartan, Dr. Lem ... Management at DNA Genotek. He holds a Medical Degree ...
(Date:4/27/2015)... Kan. , April 27, 2015  For ... cancer cells is their ability to utilize and ... alteration of cancer cells is called the ,Warburg ... in spite of high oxygen presence, leading to ... oxygen, cancer cells still choose glucose fermentation. A ...
(Date:4/27/2015)... San Diego, Calif. (PRWEB) April 27, 2015 ... mechanisms of drug and chemical toxicity carries implications for ... featured speaker April 28 at National University , ... reception and presentation by Dr. Hanzlik, a professor at ... in drug metabolism and drug design, starts at 5 ...
(Date:4/27/2015)... , 27 avril 2015 ... spécialisée dans le développement d,une nouvelle ... les infections bactériennes polypharmacorésistantes potentiellement mortelles, ... données prouvant les promesses de son ... la lutte contre la résistance aux ...
Breaking Biology Technology:Spartan Bioscience Announces Paul Lem Named Ottawa’s Top 40 Under 40 2Study Indicates Cancer Cells Alter Glucose Metabolism to Enhance Energy Production and Cell Growth 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6
... venture capital firm, hopes to make waves in ... technology companies. Also, state Assembly Republicans moved to ... studies that require destroying embryos, and the state ... Original air date: Saturday, April 16, 2005 ...
... featured speaker at the Digital Healthcare Conference 2005 ... decade, technology applied to medical records and other information has ... to more common usage. At the Marshfield Clinic , ... hands by the time medical informatics associations and journals began ...
... comes to flexible work practices women are the proverbial canaries ... many corporate career tracks is any indication, the air must ... " On Ramps and Off Ramps: Keeping Talented Women on ... The Center for Work-Life Policy and Carolyn Buck Luce of ...
Cached Biology Technology:Carl Christensen says Marshfield Clinic's history gives it an IT edge 2Carl Christensen says Marshfield Clinic's history gives it an IT edge 3Carl Christensen says Marshfield Clinic's history gives it an IT edge 4Are women opting out or shut out from career tracks? 2Are women opting out or shut out from career tracks? 3Are women opting out or shut out from career tracks? 4
(Date:4/2/2015)... HAMBURG, Germany , April 2, 2015 /PRNewswire/ ... ten fingerprint tests DERMALOG by far outperforms the ... While always maintaining high accuracy, the system is ... second. Hence, the speed proves up to be ... 40% faster than its runner-up performance. ...
(Date:4/1/2015)... 2015   Medisafe ™, the leading global medication ... iOS and Android smartphones and tablets, ... the platform to allow patients to track and correlate ... time, patients will be able to visualize in real-time ... biometrics, such as glucose levels and blood pressure. ...
(Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... lead to infertility. , Researchers at the University of Illinois ... detailed in the Proceedings of the National Academy of Sciences ... present in the uterus for pregnancy to occur. The study ... Without it, they say, an embryo cannot survive in uterine ...
... are biologically flawed. But they don't agree about what ... the basis for therapeutic cloning. , Also known ... promising approach to create individually customized cellular therapies for ... humans, it begins with stem cells derived from a ...
... estimated 7 million lives, according to the World Health ... behind this complex disease. Now, however, they have a ... In a four-year study published in the January 15 ... at The Institute for Genomic Research (TIGR) and the ...
Cached Biology News:Absence of critical protein linked to infertility 2Cloned stem cells prove identical to fertilized stem cells 2Cloned stem cells prove identical to fertilized stem cells 3Oh, rats! Designer animals reveal possible heart disease genes 2
The Trans-Blot Plus gel and cassette assembly tray is used to hold the Trans-Blot Plus gel holder cassette, buffer, and other materials for the gel and membrane sandwich during their assembly....
... mini IEF cell is an apparatus dedicated ... polyacrylamide or agarose slab gels. The cell ... electrodes, casting tray, 5 glass plates, 50 ... 5 sample templates, and instructions. Dimensions are ...
... FXP is the latest entry in the Biomek ... accuracy and increased robustness, it can meet the ... be configured with either one or two pipetting ... FXP sets the standard for flexible laboratory solutions ...
... range of next-generation features into a small-footprint ... for flexible laboratory solutions. It puts every ... dilution, dispensing, and integrations into a ... flexible as it is efficient and economical. ...
Biology Products: